Nuo Therapeutics, Inc. (AURX) SEC Filing 8-K Material Event for the period ending Monday, October 5, 2020

Nuo Therapeutics, Inc.

CIK: 1091596 Ticker: AURX

View differences made from one to another to evaluate Nuo Therapeutics, Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 8-K Corporate News to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Nuo Therapeutics, Inc..


Assess how Nuo Therapeutics, Inc.'s management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Nuo Therapeutics, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2020 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors



Material Contracts, Statements, Certifications & more

Nuo Therapeutics, Inc. provided additional information to their SEC Filing as exhibits

Ticker: AURX
CIK: 1091596
Form Type: 8-K Corporate News
Accession Number: 0001437749-20-020804
Submitted to the SEC: Tue Oct 06 2020 4:30:14 PM EST
Accepted by the SEC: Tue Oct 06 2020
Period: Monday, October 5, 2020
Industry: Surgical And Medical Instruments And Apparatus
  1. Financial Exhibit
  2. New Agreement
  3. Unregistered Sales

External Resources:
Stock Quote
Social Media

Bookmark the Permalink: